A short peptide domain of platelet factor 4 blocks angiogenic key events induced by FGF‐2

Platelet factor 4 (PF‐4) is a CXC‐chemokine with strong anti‐angiogenic properties. We have shown previously that PF‐4 inhibits angiogenesis by associating directly with fibroblast growth factor 2 (FGF‐2), inhibiting its dimerization, and blocking FGF‐2 binding to endothelial cells. We now have characterized a small peptide domain (PF‐447–70) derived from the C‐terminus of PF‐4, which conserves anti‐angiogenic effects of the parent protein. PF‐447‐70 inhibited internalization of 125I‐FGF‐2 by endothelial cells in a time‐dependent manner. The peptide reduced FGF‐2‐stimulated cell migration to control levels in wounded monolayers of bovine capillary endothelial cells. PF‐447–70 also reduced FGF‐2 induced phosphorylation of MAP kinases ERK‐1 and ERK‐2, which are essential for migration and survival of endothelial cells. In a serum‐free exvivo angiogenesis assay, the peptide blocked microvessel outgrowth by 89%. A single amino acid substitution within PF‐447–70 abolished all inhibitory activities. To simulate a real anti‐angiogenic treatment situation, we administered PF‐447–70 systemically to mice implanted subcutaneously with FGF‐2 containing gelatin sponges with the result of sparse, scattered, and immature vessel growth. The small peptide fragment derived from the angioinhibitory CXC‐chemokine PF‐4 might be used as a starting point to develop anti‐angiogenic designer drugs for angiogenesis‐dependent pathologies such as cancer, diabetic retinopathy, and rheumatoid arthritis.

[1]  R. Langer,et al.  Troponin I is present in human cartilage and inhibits angiogenesis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[2]  S. Galli,et al.  Induction of local inflammation by recombinant human platelet factor 4 in the mouse. , 1991, Cellular immunology.

[3]  Daniel B. Rifkin,et al.  Fibroblast Growth Factor-2 (FGF-2) Induces Vascular Endothelial Growth Factor (VEGF) Expression in the Endothelial Cells of Forming Capillaries: An Autocrine Mechanism Contributing to Angiogenesis , 1998, The Journal of cell biology.

[4]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[5]  Lars Holmgren,et al.  Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.

[6]  Kouji Matsushima,et al.  The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract , 1998, Nature.

[7]  D. Taub,et al.  Human Interferon-inducible Protein 10 Is a Potent Inhibitor of Angiogenesis in Vivo , 1995 .

[8]  M. Klagsbrun.  Mediators of angiogenesis: the biological significance of basic fibroblast growth factor (bFGF)-heparin and heparan sulfate interactions. , 1992, Seminars in cancer biology.

[9]  B. Dewald,et al.  Platelet factor 4 binds to interleukin 8 receptors and activates neutrophils when its N terminus is modified with Glu-Leu-Arg. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[10]  T. Gardner,et al.  Ocular neovascularization: clarifying complex interactions. , 1998, The American journal of pathology.

[11]  Y H Chen,et al.  Determination of the secondary structures of proteins by circular dichroism and optical rotatory dispersion. , 1972, Biochemistry.

[12]  William Arbuthnot Sir Lane,et al.  Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. , 1999, Science.

[13]  R. Kalluri,et al.  Canstatin, a Novel Matrix-derived Inhibitor of Angiogenesis and Tumor Growth* , 2000, The Journal of Biological Chemistry.

[14]  G. Gray,et al.  Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. , 1990, Science.

[15]  P. Nawroth,et al.  Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[16]  P. Borgström,et al.  Recombinant platelet factor 4, an angiogenic marker for human breast carcinoma. , 1998, Anticancer research.

[17]  J. Martial,et al.  Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[18]  A. Galloway,et al.  Mechanical endothelial damage results in basic fibroblast growth factor-mediated activation of extracellular signal-regulated kinases. , 1999, Surgery.

[19]  E. Ruoslahti,et al.  Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. , 1998, Science.

[20]  T. Maione,et al.  Inhibition of development of murine melanoma lung metastases by systemic administration of recombinant platelet factor 4. , 1995, Journal of the National Cancer Institute.

[21]  G. Taraboletti,et al.  The 140-kilodalton antiangiogenic fragment of thrombospondin-1 binds to basic fibroblast growth factor. , 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[22]  T. Shono,et al.  Role of thrombospondin-1-derived peptide, 4N1K, in FGF-2-induced angiogenesis. , 1999, Experimental cell research.

[23]  R. Nicosia,et al.  Endogenous regulation of angiogenesis in the rat aorta model. Role of vascular endothelial growth factor. , 1997, The American journal of pathology.

[24]  J. Boonstra,et al.  Import(ance) of Growth Factors in(to) the Nucleus , 1999, The Journal of cell biology.

[25]  P. Carmeliet.  Mechanisms of angiogenesis and arteriogenesis , 2000, Nature Medicine.

[26]  G. Gray,et al.  Inhibition of tumor growth in mice by an analogue of platelet factor 4 that lacks affinity for heparin and retains potent angiostatic activity. , 1991, Cancer research.

[27]  D. Moscatelli,et al.  High and low affinity binding sites for basic fibroblast growth factor on cultured cells: Absence of a role for low affinity binding in the stimulation of plasminogen activator production by bovine capillary endothelial cells , 1987, Journal of cellular physiology.

[28]  H. Engelhard,et al.  Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator. , 1994, Cancer research.

[29]  L. Liotta,et al.  Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor , 1990, The Journal of cell biology.

[30]  G. Neufeld,et al.  Platelet Factor-4 Inhibits the Mitogenic Activity of VEGF121 and VEGF165 Using Several Concurrent Mechanisms (*) , 1995, The Journal of Biological Chemistry.

[31]  H. Joensuu,et al.  High pre‐treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small‐cell lung cancer , 1998, International journal of cancer.

[32]  R. Strieter,et al.  Interleukin-8. A corneal factor that induces neovascularization. , 1992, The American journal of pathology.

[33]  O. Volpert,et al.  Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1 , 2000, Nature Medicine.

[34]  A. Bikfalvi,et al.  Target molecules for anti-angiogenic therapy: from basic research to clinical trials. , 2000, Critical reviews in oncology/hematology.

[35]  Integrin αvβ3 Requirement for Sustained Mitogen-activated Protein Kinase Activity during Angiogenesis , 1998 .

[36]  S. Ben‐Sasson,et al.  Inhibition of Fibroblast Growth Factor-2 Activity by a Synthetic Heparin Mimetic Modulation of Fibroblast Growth Factor-2 Receptor Binding, Dimerization, Signaling, and Angiogenic Activity by a Synthetic Heparin-mimicking Polyanionic Compound Direct Interaction between Rg-13577 and Fgf-2 Was Dem- On , 2022 .

[37]  Wei Li,et al.  VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling. , 1999, Experimental cell research.

[38]  D. Moscatelli,et al.  Basic fibroblast growth factor is internalized through both receptor-mediated and heparan sulfate-mediated mechanisms. , 1992, The Journal of biological chemistry.

[39]  P. Wen,et al.  Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth , 1997, Nature Medicine.

[40]  E. Sage,et al.  Angiostatin Diminishes Activation of the Mitogen-Activated Protein Kinases ERK-1 and ERK-2 in Human Dermal Microvascular Endothelial Cells , 1999, Journal of Vascular Research.

[41]  H. Granger,et al.  Internalized basic fibroblast growth factor translocates to nuclei of venular endothelial cells. , 1992, The American journal of physiology.

[42]  G. Gentilini,et al.  Inhibition of human umbilical vein endothelial cell proliferation by the CXC chemokine, platelet factor 4 (PF4), is associated with impaired downregulation of p21(Cip1/WAF1). , 1999, Blood.

[43]  D. Cheresh,et al.  Disruption of Angiogenesis by PEX, a Noncatalytic Metalloproteinase Fragment with Integrin Binding Activity , 1998, Cell.

[44]  K. Mayo,et al.  Heparin Dodecasaccharide Binding to Platelet Factor-4 and Growth-related Protein-α , 1999, The Journal of Biological Chemistry.

[45]  J. Richie,et al.  Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. , 1994, Journal of the National Cancer Institute.

[46]  David A. Cheresh,et al.  Regulation of Cell Motility by Mitogen-activated Protein Kinase , 1997, The Journal of cell biology.

[47]  A. Bikfalvi,et al.  Platelet factor 4 modulates fibroblast growth factor 2 (FGF-2) activity and inhibits FGF-2 dimerization. , 1998, Blood.

[48]  C. MacArthur,et al.  Receptor Specificity of the Fibroblast Growth Factor Family* , 1996, The Journal of Biological Chemistry.

[49]  A. Bikfalvi,et al.  Inhibition of in vitro angiogenesis by platelet factor-4-derived peptides and mechanism of action. , 1999, Blood.

[50]  R. Nicosia,et al.  Angiogenic role of endogenous basic fibroblast growth factor released by rat aorta after injury. , 1993, The American journal of pathology.

[51]  D. Rifkin,et al.  Autocrine activities of basic fibroblast growth factor: regulation of endothelial cell movement, plasminogen activator synthesis, and DNA synthesis , 1988, The Journal of cell biology.

[52]  R. Panek,et al.  In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase. , 1998, The Journal of pharmacology and experimental therapeutics.

[53]  M. Presta,et al.  Role of endothelial cell extracellular signal-regulated kinase1/2 in urokinase-type plasminogen activator upregulation and in vitro angiogenesis by fibroblast growth factor-2. , 1999, Journal of cell science.

[54]  Armen B. Shanafelt,et al.  The Functional Role of the ELR Motif in CXC Chemokine-mediated Angiogenesis (*) , 1995, The Journal of Biological Chemistry.

[55]  W. Risau,et al.  Mechanisms of angiogenesis , 1997, Nature.

[56]  R. Nicosia,et al.  Growth of microvessels in serum-free matrix culture of rat aorta. A quantitative assay of angiogenesis in vitro. , 1990, Laboratory investigation; a journal of technical methods and pathology.

[57]  H. Karasuyama,et al.  Recombinant interleukin 2 or 5, but not 3 or 4, induces maturation of resting mouse B lymphocytes and propagates proliferation of activated B cell blasts , 1988, The Journal of experimental medicine.

[58]  J. Richie,et al.  Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients. , 1993, Journal of the National Cancer Institute.

[59]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.